This is a clinical practice guideline for patients with multiple myeloma. The guideline provides recommendations for the treatment of both newly diagnosed and relapsed patients. Outcomes of interest include overall survival, progression-free survival, response rate, and quality of life.
We've listed guidelines under your selection of "Location". The most recent guidelines are first.
This is a clinical practice guideline for adult patients with clinically resectable or resected stage II or III rectal cancer. The guideline examines the appropriate preoperative staging tests and the role of postoperative radiotherapy (RT) and/or chemotherapy (CT) for patients with resected stage II or III rectal cancer. The primary outcomes of interest are increase in overall survival and delaying local recurrence.
This is a clinical practice guideline for patients undergoing radiation treatment for localized prostate cancer. The guideline examines the use of biodegradable spacers for prostate cancer treatment. A topic of interest is biodegradable spacer insertion as a technology that may be used to decrease toxicity and maintain quality of life (QOL) in appropriately selected patients.
This is a clinical practice guideline for patients presenting to primary care services with signs and/or symptoms of lung cancer. The guideline examines the referral process for this patient population. Topics of interest include factors that have been shown to increase the risk of lung cancer, symptoms that should be present in a person before referral, indications for chest computed tomography (CT) scan, and follow-up to diagnostic investigations.
This is a clinical practice guideline for adult and pediatric patients with suspected or diagnosed well-differentiated neuroendocrine tumours (NETs). The guideline discusses the clinical utility of Gallium-68 positron emission tomography (PET) compared with PET / computed tomography imaging for the initial diagnosis, staging, re-staging, response evaluation, and routine surveillance of patients with NETs.
This is a clinical practice guideline for adult patients with RAS wild-type unresectable metastatic colorectal cancer (mCRC) who are undergoing first-line or second-line chemotherapy. The guideline provides recommendations on the role of primary tumour location (PTL) in the selection of epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and vascular endothelial growth factor (VEGF) inhibitors, in addition to chemotherapy for the treatment of unresectable mCRC.
This is a clinical practice guideline for women with early-stage squamous cell vulvar cancer. The guideline examines sentinel lymph node biopsy (SLNB), including its safety and effectiveness in identifying women with node-negative, early-stage vulvar cancer. The appropriate procedures for SLNB in these patients are also discussed, such as selecting appropriate patients, determining the appropriate technique, and managing patients with positive sentinel lymph nodes.
This is a clinical practice guideline for women at very high risk for breast cancer. The guideline examines the effectiveness of screening using magnetic resonance imaging (MRI) in these patients, in addition to standard screening (mammography). Optimal frequency of MRI screening, subgroups that may benefit more from MRI screening, and associated harms are discussed. Workup and follow-up are also considered for those patients who have abnormal findings seen only on MRI imaging.
This is a clinical practice guideline for women with potentially curable, non-operable, locally advanced cervical cancer. The guideline provides recommendations on treatment using brachytherapy (BT), and compares different forms of BT such as two-dimensional BT, computed tomography-guided BT, magnetic resonance (MR)-guided intracavitary BT, and MR-guided intracavitary/interstitial BT. Outcomes of interest include survival, local tumour control, and toxicity.
This is a clinical practice guideline for women with ductal carcinoma in situ (DCIS) of the breast. The guideline examines the optimal surgical management of these patients, as well as radiotherapy in patients who have undergone breast-conserving surgery. The role of tamoxifen in the management of these patients is also discussed.